Our approach focuses on improving the clinical outcomes and quality of life for brain tumour patients. To achieve this we are developing innovative electrotherapy devices. Electricity has been applied to the body for the clinical management of medical conditions for decades now; two well-known examples of this are in cardiac pacemakers and deep brain stimulation for the relief of Parkinson disease symptoms. The scientific community is now starting to understand that electricity can be used to interact with a wide range of biological processes, with wide implications for the treatment of many diseases including cancer. Amongst these, a number of studies have suggested that electrical stimulation can be used to interfere with cell division. We are attempting to use this technology to slow tumour growth with the possibility that this might extend the lives of patients with brain tumours.
In many cases, the effectiveness of experimental electrotherapies is limited by the capabilities of the electronic devices delivering the therapeutic currents. To get around these issues, we are developing our device using the 2D ‘wonder’ material known as Graphene. First isolated in Manchester in 2004, graphene has unique properties including the highest electrical conductivity of any known material. We believe that the use of graphene can help optimise the performance and practical use of our device
It is important to note, that the research and technology development currently being undertaken by the company remains highly experimental at this stage, and we are still a number of years away before we could be in a position to test our device in patients.